Concarlo
Brooklyn, US · Founded 2015 · 3 known investors
Find your way into Concarlo
656 people in our graph share verified history with the Concarlo team — schools, employers, funds. One of them is your warm intro.
Ken Chenaultunlockedknows Stacy Blain · together at Chief (overlapped)
×3knows the team · via Creative Destruction Lab
knows the team · via Columbia University
×2knows the team · via Princeton University
×4knows the team · via Chief
knows the team · via SUNY Downstate Medical Center
Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
Founders & leadership
Concarlo was founded in 2015 by Stacy Blain.
SB
Stacy Blainin𝕏Founder, CEOA cancer biologist who spent two decades as an associate professor in the departments of cell biology and pediatrics at SUNY Downstate Medical Center, she moved her laboratory research on cell cycle regulation toward commercialization in 2016. She has taken part in the Springboard Enterprises healthtech cohort and the Creative Destruction Lab cancer stream, and is a member of Chief.
LC
LisaMarie CaseyPresident and Manager
Board
JM
Investors · 3
Reported raises · per SEC filings
Form D private placements$450K disclosed across 1 round · 2017
▶$450KraisedMar 2017 · 6 investors · BiotechnologyRule 506(b)
▶$450KraisedMar 2017 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- LisaMarie CaseyExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $450K
- Minimum investment
- $25K
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapApplied Therapeutics7 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Protara Therapeutics6 shared keywordsProtara develops transformative therapies for patients with cancer and rare diseases, applying modern scientific and manufacturing advancements to accelerate drug development.
Capricor6 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Certara6 shared keywordsCertara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.
Companies competing with Concarlo for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Concarlo do?
- Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
- Who founded Concarlo?
- Concarlo was founded by Stacy Blain in 2015.
- Who are Concarlo's investors?
- Concarlo's investors include BioAdvance, Creative Destruction Lab (CDL), Raptor Group.
- How much funding has Concarlo raised?
- Concarlo has disclosed $450K raised across 1 round.
- Where is Concarlo headquartered?
- Concarlo is headquartered in Brooklyn, US.